<DOC>
	<DOC>NCT01469182</DOC>
	<brief_summary>This study assessed the safety profile of short ragweed (Ambrosia artemisiifolia) in participants with ragweed-induced rhinoconjunctivitis with or without asthma. The primary objective was to compare treatment-emergent adverse events (AEs) for participants treated with short ragweed allergy immunotherapy tablet (AIT) with those treated with placebo.</brief_summary>
	<brief_title>A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Clinical history of physiciandiagnosed ragweedinduced allergic rhinoconjunctivitis of 2 years duration or more, with or without asthma Must have a positive skin prick test response to Ambrosia artemisiifolia Must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value Clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor Females of childbearing potential must agree to use medically accepted methods of contraception Unstable asthma or has experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids in previous 3 months Received an immunosuppressive treatment within 3 months History of anaphylaxis with cardiorespiratory symptoms. History of chronic urticaria or angioedema Current severe atopic dermatitis Female subject who is breastfeeding, pregnant, or intending to become pregnant Has received maintenance doses of immunotherapy with ragweed extract for â‰¥1 month within the last 5 years History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or selfinjectable epinephrine Unable to or will not comply with the use of selfinjectable epinephrine Participating in any other clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immunology</keyword>
</DOC>